To the full analysis
BioMarin Pharmaceutical stock: growth
BMRNBioMarin Pharmaceutical reported $3.22B in revenue for fiscal 2025, up 12.9% on the prior year, up 11.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
21.1%
per year from 2006 to 2025, per share 16%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.6% | 13.7% | 21.1% |
| Revenue per share | 10.3% | 11.7% | 16.0% |
| Earnings | −16.4% | no data | no data |
| Earnings per share | −17.5% | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $84.21M | −$28.53M | −$74.67M |
| 2007 | $121.58M | −$15.8M | −$56.91M |
| 2008 | $296.49M | $30.83M | −$65.54M |
| 2009 | $324.66M | −$488K | −$2.07M |
| 2010 | $376.27M | $205.82M | −$30.72M |
| 2011 | $441.36M | −$53.84M | −$135.47M |
| 2012 | $500.72M | −$114.35M | −$26.96M |
| 2013 | $548.49M | −$176.35M | −$124.76M |
| 2014 | $749.28M | −$133.97M | −$192.37M |
| 2015 | $889.9M | −$171.8M | −$449.34M |
| 2016 | $1.12B | −$630.21M | −$376.22M |
| 2017 | $1.31B | −$117.04M | −$207.98M |
| 2018 | $1.49B | −$77.21M | −$124.41M |
| 2019 | $1.7B | −$23.85M | −$96.76M |
| 2020 | $1.86B | $854.03M | −$52.15M |
| 2021 | $1.85B | −$64.08M | $185.31M |
| 2022 | $2.1B | $141.56M | $54.94M |
| 2023 | $2.42B | $167.65M | $51.65M |
| 2024 | $2.85B | $426.86M | $475.42M |
| 2025 | $3.22B | $348.9M | $724.96M |
Revenue by segment
How BioMarin Pharmaceutical Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product98%
- Royalty And Other2%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Product | $2.81B | $3.17B | 98.3% |
| Royalty And Other | $44.47M | $53.49M | 1.7% |
| Total revenue | $2.85B | $3.22B | 100% |
Revenue by region
Where BioMarin Pharmaceutical Inc. generates its revenue.
- United States49%
- Europe28%
- Rest of world12%
- Latin America11%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | Share 2020 | |
|---|---|---|---|---|---|---|
| United States | $507.54M | $588.24M | $696.79M | $778.44M | $912.38M | 49% |
| Europe | $252.63M | $301.49M | $436.43M | $509.19M | $518.47M | 27.9% |
| Rest of world | $209.21M | $241.48M | $172.94M | $197.63M | $223.75M | 12% |
| Latin America | $147.47M | $182.44M | $185.05M | $218.79M | $205.86M | 11.1% |
| Total revenue | $1.12B | $1.31B | $1.49B | $1.7B | $1.86B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 13 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.